|
|
|
|
|
|
|
|
|
Meeting Higher Standards for
Bedside Glucose Testing
Transitioning to New Technology for
Improved Accuracy and Patient Safety |
|
|
|
|
|
The FDA, CLSI, ADA, Society of Critical Care Medicine (SCCM), and Association of Clinical Endocrinologists (AACE) are proposing new standards for improved accuracy of bedside glucose monitors. Published reports and clinical experience indicate that current ISO 15197 standards are inadequate and can cause erroneous glucose results, inappropriate insulin doses and adverse events related to glycemic control of hospitalized patients. As adverse incidents and even deaths are still being reported, the need for tighter standards and more accurate technology for bedside testing has become imperative.
This P.A.C.E® accredited educational seminar will discuss issues surrounding glycemic control of hospitalized patients, proposed standards, and hospital experience implementing a new technology that meets higher accuracy standards for bedside glucose testing.
Presentations include:
- Causes and consequences of glucose alterations in hospitalized patients
- Outcomes associated with glycemic control protocols
- Issues confounding the delivery of accurate bedside glucose testing
- A new technology that meets higher standards for accurate, safe bedside glucose testing
- Hospital experience selecting and transitioning to a new bedside glucose partner
The patented, interference-free Nova Biomedical StatStrip Hospital Glucose Monitoring System will be described. Data will be summarized from over 50 published, hospital studies characterizing the improved accuracy of this new technology at wide ranges of glucose and with common interferences such as hematocrit, maltose, and oxygen. Presentations by hospital point of care staff will describe their selection process and practical experience transitioning to this new bedside glucose system. |
|
|
|
|
|
|
This seminar will be beneficial to: |
|
|
|
|
|
|
POC Supervisors
Laboratory Managers
Nursing Directors
Diabetes Educators |
|
|
|
|
|
|
|
William Clarke, Ph.D.
Director of TDM and Toxicology
Director POCT, Dept of Pathology
Johns Hopkins School of Medicine, Baltimore, MD |
|
|
|
|
|
|
|
|
Sheila Cruthis, MT (ASCP)
Point of Care Coordinator
Moses Cone Health System, Greensboro, NC |
|
|
|
|
|
|
|
|
T. Scott Isbell, Ph.D.
Director, Medical & Scientific Affairs
Nova Biomedical, Waltham, MA |
|
|
|
|
|
|
|
|
| 8:00 a.m. - 9:00 a.m. |
|
Registration & Continental Breakfast
|
| 9:00 a.m. - 10:30 a.m. |
|
Overview of Glucose Alterations in Inpatient Settings: Causes and Consequences
William Clarke, Ph.D.
New Glycemic Management Protocols, Requirements, Outcomes and Proposed Glucose Meter Standards
William Clarke, Ph.D.
Analytical Obstacles to Effective Bedside Glucose Testing
T. Scott Isbell, Ph.D.
|
| 10:30 a.m. - 10:45 a.m. |
|
Break
|
| 10:45 a.m. - 12:30 p.m. |
|
New Technology for Bedside Glucose Testing That Eliminates Errors From Hematocrit, Maltose, and Electrochemical Interferences
Ron Newby, Director of Marketing, Nova Biomedical
Selection and Implementation of a New Bedside Glucose Testing System—A Point of Care Manager’s Perspective
Sheila Cruthis, MT (ASCP)
|
| 12:30 p.m. |
|
Lunch |
|
|
|
|
The seminar and course materials are provided at no charge. |
|
|
|
|
|
|
Nova Biomedical is approved as a Provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® program. This seminar provides 2.5 contact hours for P.A.C.E.® continuing education credits. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
